MAPT and Alzheimer disease: To study CH individuals with early AD pathology and compare it with dementia, we analyzed CSF Aβ42 and tau from individuals with clinical diagnoses ranging from healthy to dementia, including a CH cohort with an increased likelihood of preclinical pathology because of advancing age (Harrington et al., 2013).